The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study
Open accessAbstract
Varicella-zoster virus (VZV) disease occurs in 30% of allogeneic hematopoietic cell transplant recipients who had a history of VZV infection. A safe and effective prevention strategy has not been established. In a double-blind controlled trial, 77 hematopoietic cell transplant recipients at risk for VZV reactivation were randomized to acyclovir 800 mg twice daily or placebo given from 1 to 2 months until 1 year after transplantation. VZV disease at 1 year was the primary end point; VZV disease after discontinuation of prophylaxis, VZV-specific T-cell immunity, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) disease, survival, and safety were secondary end points. Acyclovir significantly reduced VZV infections at 1 year after transplantation (HR, 0.16; 95% CI, 0.035-0.74; P = .006). In the postintervention observation period, this difference was not statistically significant (2 years: HR, 0.52; 95% CI, 0.21-1.3; 5 years: HR, 0.76; 95% CI, 0.36-1.6). There was no statistically significant difference in reconstitution of VZV-specific T-helper cell responses, HSV infections, CMV disease, chronic graft-versus-host disease, and overall survival between the groups. Acyclovir was well tolerated. Post-study VZV disease predominantly occurred in patients with continued need for systemic immunosuppression. In conclusion, acyclovir effectively and safely prevents VZV disease during the first year after hematopoietic cell transplantation. Periods of prophylaxis longer than 12 months may be beneficial for those hematopoietic cell transplant recipients on continued immune suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
(2000) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(00)70002-4 · Cited by 607
Storek, J., Dawson, M. A., Storer, B., Stevens-Ayers, T., Maloney, D. G., Marr, K. A., Witherspoon, R. P., Bensinger, W., Flowers, M. E. D., Martin, P., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3380 · Cited by 397
Self-citationTreatment of Varicella–Zoster Virus Infection in Severely Immunocompromised Patients
Shepp, D. H., Dandliker, P. S., & Meyers, J. D. (1986) · New England Journal of Medicine · doi:10.1056/nejm198601233140404 · Cited by 307
Self-citationUse of an Inactivated Varicella Vaccine in Recipients of Hematopoietic-Cell Transplants
Hata, A., Asanuma, H., Rinki, M., Sharp, M., Wong, R. M., Blume, K., & Arvin, A. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013441 · Cited by 300
Duration of immunosuppressive treatment for chronic graft-versus-host disease
Stewart, B. L., Storer, B., Storek, J., Deeg, H. J., Storb, R., Hansen, J. A., Appelbaum, F. R., Carpenter, P. A., Sanders, J. E., Kiem, H.-P., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0200 · Cited by 281
Self-citationPrentice, H. G., Gluckman, E., Powles, R., Ljungman, P., Milpied, N. J., Fernandez-Rañada, J. M., Mandelli, F., Kho, P., Bell, A. R., & Kennedy, L. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91835-x · Cited by 273
Koc, Y., Miller, K. B., Schenkein, D. P., Griffith, J., Akhtar, M., DesJardin, J., & Snydman, D. R. (2000) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(00)70051-6 · Cited by 233
Wilson, A., Sharp, M., Koropchak, C. M., Ting, S. F., & Arvin, A. M. (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/165.1.119 · Cited by 192
Ljungman, P., de la Camara, R., Milpied, N., Volin, L., Russell, C. A., Crisp, A., Webster, A., & the Valacyclovir International Bone Marrow Transplant Study Group (2002) · Blood · doi:10.1182/blood.v99.8.3050 · Cited by 185
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Self-citationFlowers, C. R., Seidenfeld, J., Bow, E. J., Karten, C., Gleason, C., Hawley, D. K., Kuderer, N. M., Langston, A. A., Marr, K. A., Rolston, K. V. I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8661 · Cited by 448
Erard, V., Wald, A., Corey, L., Leisenring, W. M., & Boeckh, M. (2007) · The Journal of Infectious Diseases · doi:10.1086/518938 · Cited by 121
Self-citationLaws, H.-J., Baumann, U., Bogdan, C., Burchard, G., Christopeit, M., Hecht, J., Heininger, U., Hilgendorf, I., Kern, W., Kling, K., et al. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03123-w · Cited by 88
Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant
Sutrave, G., Blyth, E., & Gottlieb, D. J. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.012 · Cited by 20
Metadata
- Authors
- Boeckh, M., Kim, H. W., Flowers, M. E. D., Meyers, J. D., & Bowden, R. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-03-01
- Volume
- 107
- Issue
- 5
- Pages
- 1800-1805
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2039773104
- Cited by
- 255
- References
- 20
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. https://app.cochat.ai/papers/10.1182/blood-2005-09-3624
- The paper
- Boeckh, M., Kim, H. W., Flowers, M. E. D., Meyers, J. D., & Bowden, R. A. (2006). Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood. https://doi.org/10.1182/blood-2005-09-3624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
